Cytokine-mobilized peripheral blood progenitor cells (PBPCs) have been used successfully for hematopoietic reconstitution following allogeneic transplantation. The ease of harvest, the faster engraftment and the high yield of CD34 + cells have made this source of hematopoietic progenitor cells (HPCs) an attractive alternative to bone marrow (BM). In the present study we compared the engraftment potential of conventional BM allografts and single leukapheresis products (LPs) collected from healthy donors following the administration of granulocyte colony-stimulating factor (G-CSF). For this, lineage-committed and primitive HPCs were assessed by flow cytometry and by colony-and cobblestone areaforming cell (CFC, CAFC) assays. Mean numbers of CD34 + cells in LPs (n = 11) were similar to that of BM grafts (n = 12) (278 ± 57 vs 227 ± 34 × 10 6 CD34 + cells). The frequencies of CFCs, week 5 CAFCs and week 8 CAFCs were 1.6-, 8.4-and 10.3-fold higher in the CD34 + compartment of mobilized blood than that of marrow, resulting in significantly higher yields of clonogenic HPCs in LPs when compared to BM grafts. We conclude that G-CSF preferentially mobilizes clonogenic progenitors capable of short-and, in particular, longterm reconstitution, and that the engraftment potential of single LPs is superior to that of BM allografts. Hence, the use of PBPCs may be favorable for protocols that include graft manipulations with expected cell loss (eg T cell depletion, CD34
Peripheral blood progenitor cells (PBPCs) collected after the administration of recombinant human granulocyte colony-stimulating factor (G-CSF) are capable of rapid and sustained hematopoietic reconstitution following allogeneic transplantation. [1] [2] [3] Current experience, with follow-up exceeding 4 years, suggests that the side-effects of G-CSF application are tolerable to healthy donors. In addition, harvesting of PBPCs is more comfortable and safe for the donors, compared to BM aspiration under general anesthesia. 4 Recent studies have demonstrated that HLA-identical sibling transplantation using PBPCs is associated with a lower incidence of toxicity, earlier discharge, and no higher incidence of acute graft-versus-host disease when compared to the use of BM. However, the most striking difference between PBPCs and BM is the faster recovery of neutrophils and platelets. 5, 6 These findings are considered to be dependent on the higher numbers of HPCs in PBPC transplants 6, 7 and parallel the clinical benefits of PBPC grafts over BM grafts in the autologous transplant setting. 7, 8 The yield of HPCs in allo-and autografts is routinely assessed by the enumeration of CD34 + cells. [5] [6] [7] [8] The CD34
+ population, however, is heterogeneous with differences in the relative frequencies of lineage-committed and primitive HPCs. These differences are dependent on both the interindividual variation and the source of HPCs. [9] [10] [11] Primitive HPCs have been characterized as CD34 + cells that co-express Thy1 12 or lack the differentiation-associated antigens CD38 and HLA-DR. 13, 14 They have further been defined as long-term culture initiating cells (LTC-ICs) due to their ability to initiate and sustain the production of daughter cells for at least 5 weeks in stroma supported longterm cultures (LTCs). Clonal activity of LTC-ICs may be scored by wells positive for replatable colony-forming cells 15 or directly by microscopy, as they form intrastromal cell clusters resembling cobblestone areas (CAs). 16 Murine studies have indicated that the number of primitive rather than committed progenitors predicts short-and long-term reconstitution following allogeneic transplantation. 17, 18 Although similar studies in man are not available, the enumeration of primitive HPCs may currently be regarded as the best option to determine the engraftment potential of PBPC and BM allografts.
However, there are hardly any data regarding the content of primitive HPCs in clinical scale allografts. To address this subject we compared the engraftment potential of single LPs and BM allografts harvested from healthy donors. For this, absolute numbers of both lineage-committed and primitive progenitors were determined by means of CD34 + cell and CD34 + subset analysis as well as colony-and cobblestone area-forming cell assays.
Materials and methods

Collection of LPs and BM
PBPCs and BM were harvested from healthy HLA-matched sibling donors. Donor characteristics and harvesting results of single LPs and BM allografts are summarized in Table 1 . The PBPC donors received 5 g/kg of G-CSF (Neupogen, Roche, Hvidovre, Denmark) subcutaneously every 12 h until completion of the collection. Leukapheresis was started on day 5 of G-CSF administration. Up to four single LPs were harvested to obtain one whole PBPC allograft. The donor venous access was obtained through bilateral cubital venipuncture and the PBPCs harvested using a continuous flow blood cell separator (Cobe Spectra, Cobe Laboratories, Lakewood, CO, USA). The BM grafts were collected from the posterior iliac crest under general anesthesia according to institutional standard procedures. Samples from LPs (1 ml) and BM grafts (10 ml) were collected and analyzed immediately after the completion of harvest. All samples were obtained following informed consent according to the guidelines established by the Ethical Committee of the Cities of Copenhagen and Frederiksberg.
CD34
+ cells and CD34 + subsets
The enumeration of CD34 + cells was carried out on cell samples before and after Lymphoprep separation (density The flow cytometry analysis was performed on a FACScan (BDIS) using CellQuest software (BDIS). Side scatter (SSC), forward scatter (FSC) and three fluorescence signals were determined for single cells and stored as list mode data files. A minimum of 3000 cells was acquired in a CD34 gate based on fluorescence intensity and SSC level, accepting 0.1% and 0.5% false positive events in LPs and BM control samples, respectively. Analysis was performed using the PC Lysis software (BDIS). By backgating the CD34 + population in the FSC vs SSC dot plot only events of lymphoblastoid character were accepted for quadrant analysis. The percentage of false positive events accepted in the control samples was exactly in the range of 0.9-1.1% for each fluorescence. For enumeration of CD34 + subsets, their frequencies were multiplied by the total numbers of CD34 + cells in LPs and BM grafts. This approach was accepted for quantification of CD34 + subpopulations as previous investigations had shown no selective loss of specific subsets in the MNC fraction when compared to unseparated samples. 20 
Colony assay
Committed HPCs were examined by colony formation in semisolid culture assays. Unseparated cell samples were cultured in duplicate at 0.25, 0.5 and 1.0 × 10 5 cell/ml in semisolid medium (StemCell Technologies, Vancouver, Canada; composition: 0.9% methylcellulose, 30% fetal calf serum, 1% bovine serum albumin, 0.1 mm 2-mercaptoethanol, 2 mm l-glutamine, 3 units/ml erythropoietin, 50 ng/ml stem cell factor, 20 ng/ml GM-CSF, 20 ng/ml IL-3, 20 ng/ml IL-6, 20 ng/ml G-CSF). After 18 days of incubation in a water saturated atmosphere at 37°C and 5% CO 2 the colony formation was evaluated by inverted microscopy. Colonies of у40 cells were enumerated and classified as colony-forming unit, granulocyte, macrophage (CFU-GM), burst-forming unit, erythrocyte (BFU-E) and colony-forming unit, granulocyte, erythrocyte, megakaryocyte, macrophage (CFU-GEMM) according to their morphology. 21 
Cobblestone area forming cell assay
Frequencies of primitive clonogenic HPCs were quantified by using the CAFC assay as described previously. 18 The murine FBMD-1 stromal feeder cell line (kindly provided by Dr RE Ploemacher, Dept of Hematology, Erasmus University, Rotterdam, The Netherlands) was cultured in Iscove's modified Dulbecco's medium (IMDM including Glutamax, Gibco, Life Technologies, Roskilde, Denmark) supplemented with 10% FBS, 5% horse serum (HS) (StemCell Technologies), hydrocortisone 21-hemisuccinate (1 m final concentration; Sigma) and penicillin/ streptomycin (100 U/ml and 100 g/ml final concentration; Life Technologies). Eight milliliters of stromal cell suspension were incubated in 80 cm 2 culture flasks with filter cap (Nunc, Roskilde, Denmark) in a water saturated atmosphere of 5% CO 2 at 33°C. Cells were harvested just before reaching confluence (approximately 1 week) by trypsinisation (0.5% trypsin/0.2% EDTA solution; Life Technologies), then passed through a ␥-irradiated 80 m nylon filter (Millipore, Hedehusene, Denmark) and washed with IMDM/10% FBS. For expansion, stromal cells derived from one flask were resuspended in 24 ml of FBMD-1 medium and seeded into three new culture flasks. For the CAFC assay, stromal cells were resuspended at a final concentration of 1000 cells/100 l into Dexter culture medium (StemCell Technologies) supplemented with 1 m hydrocortisone 21-hemisuccinate, 100 U/ml penicillin, 100 g/ml streptomycin, 10 ng/ml IL-3, 20 ng/ml G-CSF. To improve the adherence of the stromal cells, 96-well plates (flat-bottomed, Nunc) were incubated for at least 24 h at 4°C with bovine dermal collagen (Cellon collagen 3.0 mg/ml; Cellon Sàrl, Strassen, France) diluted 1:45 with PBS. Wells were washed with PBS before seeding the stromal feeder cells. The FBMD-1 cell line was used between the 13th and 19th passage. For each CAFC assay only the central 60 wells of two 96-well plates were inoculated with feeder cells (100 l containing 1000 cell/well). The two 96-well plates and one open dish (97 × 17 mm; Nunc) containing distilled water were then placed in a closed but ventilated culture dish (245 × 245 mm; Nunc) and incubated for 10 days to ensure confluence and sufficient adhesion of the stromal feeder layer.
For the CAFC assay, MNCs were resuspended in modified Dexter medium. Then, the stromal feeder layers were overlaid with 100 l of MNCs suspension at limiting dilutions. The cell input ranged from 390 to 50 000 MNCs (eight dilutions two-fold apart) with each dilution seeded in 15 replicate wells. Plates were incubated in a water-saturated atmosphere of 5% CO 2 at 33°C and fed weekly by semidepletion. After 5 and 8 weeks of culture, wells were scored for CAs using an inverted phase contrast microscope. CAs were defined as nonrefactory cell clusters of at least five cells. The frequency of CAFCs/MNCs was calculated from the proportion of CA-negative wells using SAS software (SAS Institute, Cary, NC, USA) and Poisson statistics as described previously. 22, 23 Based on the knowledge of CD34
+ cell and CAFC frequency in the MNC population the proportion of CAFCs within the CD34 + population was calculated. The latter was multiplied by the yield of CD34 + cells in LPs and BM grafts to determine their total numbers of CAFCs.
Statistics
Statistical analysis was performed by using the GraphPad software (San Diego, CA, USA). The results are expressed as mean ± standard error of mean (s.e.m.). Statistical significance between LPs and BM grafts was determined by the two-tailed Mann-Whitney test. Correlation between flow cytometry data and in vitro assays was evaluated by linear regression analysis. A significance level of P Ͻ 0.05 was chosen.
Results
TNCs and CD34
+ cells
The yield of TNCs and CD34 + cells in single LPs and BM allografts are depicted in Table 1 . Absolute numbers of TNCs in single LPs were slightly but significantly increased when compared to BM grafts (1.6-fold; P = 0.001). The mean number of CD34 + cells in single LPs was similar to that of BM grafts (1.2-fold higher; P = 0.44).
Regression analysis revealed no correlation between TNC yield and CD34
+ cell yield for either graft type. The frequency of CD34 + cells within the leukocyte (CD45 + ) population of LPs was 0.77 ± 0.15% before and 0.61 ± 0.1% following density separation. In BM grafts, 0.99 ± 0.13% of unseparated cells and 2.94 ± 0.41% of density separated cells were CD34 + /CD45 + .
CD34 + subsets
The expression of CD38 and HLA-DR antigens, as measured by the mean fluorescence intensity (MFI) was significantly lower for PBPCs than for BM CD34 + cells (two-fold for CD38, P = 0.0003; two-fold for HLA-DR, P = 0.0002). CD34 + subset analysis, however, showed similar numbers and frequencies of primitive subsets characterized as CD34 + /CD38 − , CD34 + /HLA-DR − , CD34 + /CD38 − /HLA-DR − and CD34 + /Thy-1 + in LPs and BM grafts (Tables 2  and 3 ).
Colony and cobblestone area forming cells
Except for the CFU-GM progenitors, all clonogenic HPCs were significantly increased in single LPs when compared Figure 3 illustrates that the blood-derived CD34 + population contained a significantly higher percentage of clonogenic progenitors than the CD34 + population of BM. The frequency of total CFCs was only 1.6-fold higher, whereas the more primitive week 5 CAFCs and week 8 CAFCs were present at an 8.4-fold and 10.3-fold higher frequency in the CD34 + compartment of LPs than BM grafts, respectively.
Correlation of flow cytometry and clonogenic assays
The yield of CFCs were correlated with the yield of CD34 
BFU-E 14%
CFU-GM 19%
BFU-E 33% Figure 3 The CD34 + compartments of BM and G-CSF-mobilized PBPC are illustrated by the hierarchical order of HPCs. Week 8 CAFCs were depicted as the most primitive HPCs and non-clonogenic lineage-committed progenitors (E = erythroid, M = monocytoid, G = granulocytic) as the most mature HPCs. The width of the figures is directly correlated to the frequencies of each progenitor subpopulation. The frequencies of clonogenic progenitors were calculated as the number of CFCs or CAFCs/number of CD34 + cells × 100% in a given sample. Table 4 BM allografts: regression analysis Significant results in bold.
247
Total No. of cell CFCs week 5 CAFCs week 8 CAFCs types in BM allografts
Table 5
Single LPs: regression analysis
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TNCs r in PBPC transplants. 24, 25 Finally, studies have shown a qualitative difference between the CD34 + population of mobilized PB and that of BM. 9, 26, 27 Currently, little is known about the quantitative differences of primitive HPCs in PBPC and BM transplants collected from healthy donors. In the present study we compared the engraftment capacity of single LPs and BM allografts by enumeration of HPCs. Late progenitors were determined by CD34
+ cell analysis and colony formation, whereas early progenitors were assessed by CD34
+ subset analysis and scoring of LTC-ICs after 5 and 8 weeks in the CAFC assay.
Single LPs and BM grafts contained equal numbers of CD34 + cells. + /HLA-DR − subsets. The expression of CD38 and HLA-DR antigens on blood but not on marrow-derived week 5 LTC-ICs indicates that G-CSF induces up-regulation of differentiation antigens on primitive clonogenic progenitors. Although this process generally is associated with loss of hematopoietic potency, successful long-term engraftment following PBPC transplantation indicates no such loss of hematopoietic potency. In fact, CAFCs from LPs have a higher colony efficiency when compared to BM-derived CAFCs. 27 Thus, the CD38 and HLA-DR antigen expression on week 5 CAFCs in LPs may not be associated with a decrease of engraftment potential. This might be due to the presence of high numbers of more primitive week 8 CAFCs that compensate for loss of hematopoietic potency in the week 5 CAFC subpopulation. One might even speculate that the up-regulation of differentiation antigens on week 5 CAFCs is a transient phenomenon during circulation that is reversed upon homing to the BM microenvironment. Recently, a CD34-negative population has been defined, that is of mononuclear character and highly enriched for primitive hematopoietic progenitors including LTC-ICs. 28 In our study MNCs were used in the CAFC assay and consequently such a clonogenic CD34-negative population may at least partially explain the difference between yields of week 5 CAFCs and primitive CD34 + subsets in LPs. Several factors such as graft processing, pretreatment of the patient, and HLA disparity between donor and recipient determine the number of HPCs needed for successful clinical engraftment. Currently, allogeneic transplantation is routinely performed by using BM grafts containing a minimum number of 2 × 10 8 TNC/kg body weight of the recipient. Based on our data we calculated that this BM threshold dose would provide an average of 6.1 × 10 3 week 5 and 1.9 × 10 3 week 8 CAFC/kg body weight. Considering these numbers of primitive progenitors/kg as the threshold dose for allogeneic transplantation, we estimated that the apheresis of 1.0-1.5 l of mobilized blood (or 2-3 blood units) would be sufficient to obtain equal target doses of week 5 and week 8 CAFCs. This is in contrast to Baumann et al, 29 who argued that 0.5 l blood from G-CSF-mobilized donors may be sufficient for allogeneic engraftment. However, their calculations were based on blood samples obtained from G-CSF-mobilized patients pretreated for advanced breast cancer. Moreover, they estimated the numbers of primitive HPCs in single cultures as the number of CFU-GM per MNCs seeded on a pre-established irradiated BM stroma. In contrast, we directly enumerated primitive HPCs using the CAFC assay with a limiting dilution set-up. Considering these differences in study design our results are comparable to those of Baumann et al.
Of interest, we found that single LPs despite low CD34 + cell numbers contained several fold higher numbers of CAFCs than conventional marrow grafts. Hence, collection of 2-3 LPs would not only supply the recipient with an adequate graft, but also allow cryopreservation of sufficient cell numbers for future treatment in case of need for retransplantation due to relapse. 30 Moreover, harvesting of PBPCs rather than BM may be of advantage for clinical protocols that include graft manipulation with loss of cells, such as CD34
+ enrichment and T cell depletion. Finally, the higher numbers of potential target cells (eg CAFCs) may favor the use of PBPCs in gene therapy protocols.
In summary, we found that G-CSF preferentially mobilizes clonogenic HPCs resulting in a significantly higher yield of short-and, in particular, long-term reconstituting progenitors in single LPs when compared to conventional BM allografts. PBPCs may therefore eventually replace BM as a source of HPCs when these attributes are crucial for the clinical outcome.
